ARTICLE | Targets & Mechanisms
Following PARP, ATR axis next in line to expand synthetic lethal drug class
As companies search for the successor to PARP, the ATR axis becomes a key contender
June 7, 2019 3:07 AM UTC
Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing.
Biomarker and combination strategies presented at the American Society of Clinical Oncology meeting indicate the thinking may need to go beyond simple two-way synthetic lethal interactions like PARP-BRCA, which involve one inhibitor plus one mutation...